February was an interesting month, stocks went up an then came down as long-term interest rates started to rise. For me, the interest rate changes are not that important, even if it impacts companies negatively with higher financing costs. GameStop was still a topic discussed in Financial media as the stock rose again at the end of February. Covid is still not beaten and Biden with Congress approved a new stimulus package.
My portfolio rose a bit in February as January ended in a large decline, January ended at +1,54% while February landed at +4,78%. There were a few increases to positions made and also a few new investments. One driver to the increase was People's United Financial which will be acquired by M&T Bank, will receive approximately 9 shares in M&T Bank and some change given that the acquisition is approved. Did not expect People's to be acquired this soon, yet based on its valuation it was an attractive acquisition object and now M&T Bank will get it at a decent price. For more details you can check People's and M&T Banks Investor news as well as barrons.com
During February my portfolio received 66,36€ in gross dividend and 56,57€in net dividends. AT&T represented over 50% of dividend in February which does highlight the risk in case they have to postpone dividend payments or decrease it. People's United Financial was the second biggest with 13,31€ gross and 11,31€ net. So far this year I have received 246,39€ in net dividends and the biggest parts are still to come.
Changes to portfolio
New investments
Bought 1 share in SPDR S&P Global Dividend Aristocrats UCITS ETF at 27,01€ including transaction costs. The idea is to increase this position over time and most likely also buy in the US Dividend Aristocrat ETF for long run. Will also buy the individual companies from time to time and waiting for the market to drop a bit in order to increase these positions. Wrote about dividend aristocrats back in December 2020 and now decided to invest in one ETF holding these known and proper companies. Link to post.
Fresenius AG was added to my portfolio, 4 shares at 35,03€. It represents 0,32% of my portfolio at the moment. A short introduction to Fresenius AG, it is a medical company and one of the largest shareholders of Fresenius Medical Care is a renal disease focused company. It owns Fresenius Kabi a mainly transfusion company focused on seriously and chronically ill patients. Fresenius Helios is a private hospital operator in mainly in Europe but also a few hospitals in Latin Amerika. Fresenius Vamed is a project management company focused on health care facilities. 2020 Reported earnings per share was 3,06€ vs 3,38€ 2019 this gives the company a P/E-ratio of 11,61 and equity ratio was 39%. Compared to many other medical companies I find Fresenius at value in the long run as most likely Covid will be beaten at some point.
Bought a bit of Handelsbanken Latin Amerika fund for 30€ as the market has been heavily hit by Covid, this increases the upside potential once vaccines have been distributed and people can return to a more normal life.
Old positions
AT&T
Bought 6 shares in AT&T since the last update. Recongized that their earnings per share has not developed in a best case way, yet the company is a good long run hold as long as they do not overleverage. The weighted average purchase price per share dropped a little from $31,38 to $31,22. Still looking forward to proper dividends in May.
BCE
Bought 2 shares in BCE as the price dropped below my purchase price, the weighted average purchase price remained the same at CAD 54,82 per share. It seems like telecom companies are not hot right now and therefore the prices have been declining. Maybe the 5G investments and competition is driving this yet shall see.
Beiersdorf AG
Increased the position by 2 shares from 3 to 5, paid price decreased from 92,84€ to 90,16€. The price seemed to decline due to lower earnings than expected yet, was proper from my personal view. The company has been making a positive result for a long time now which compared to many companies is exceptional. The dividend is a bit of a disappointment, however better than nothing.
Pfizer
Increased my position in Pfizer from 6shares to 12, the weighted average paid price increased from $30,69 to $32,45. In euros the weighted price paid by share dropped a bit which might confuse as the US dollar price increased. Overall I find Pfizer a solid long term investment and I am surprised that the price does not reflect their well working vaccine, compared to Johnson&Johnson which has had a rising stock price yet still not launched any vaccine even though they heavily have invested in the development.
PPL Corp
Increased my PPL position from 6 shares to 12 and the price increased from $26,68 to $27,13, in euros I paid about the same per share as before. PPLs Q4 was apparently a disappointment for markets which saw the stock decline a bit. For me even though the company has some debt, based on cash flow it will be able to pay off most of the debt in a short period.
Telia
Bought 10 shares in Telia as the market price declined, it is the largest position in my portfolio with a 9,63% weight. For some this weight would be too big and they would increase other positions or divest some of the investment to balance it around 5%. As my investment horizon is not 3 months the size of a single position can be large from time to time and it will not bother me. Have however noted that small movements in Telias share price will have a big impact on my portfolios market value.
Waiting for March to start, a bit of dividends will come in during the first week which might give opportunities to buy some more shares. Overall, the turbulent markets are not concerning me.
The company review I mentioned in beginning of February is to come, still need to check a few annual reports and then it will be revealed. February was just really busy month for me with tax declarations, finalization of 2020 accounts and a lot of other funny financial stuff.
No comments:
Post a Comment